Trick, or treat? FDA plans Hal­loween ad­comm for Ipsen’s sec­ond chance at rare dis­ease drug

3 years ago
FDA+

Gilead se­cures first lenaca­pavir ap­proval in Eu­rope af­ter lengthy man­u­fac­tur­ing de­lays

3 years ago
R&D
FDA+

Flush with $126M raise, Tes­sa Ther­a­peu­tics woos new CEO from Take­da

3 years ago
People

Backed by Medicxi, No­var­tis vets launch rare blood dis­or­der biotech with fresh take on drug class used in can­cers

3 years ago
Financing
Startups

Roche's big Chi­na play; Mer­ck bets on mR­NA, again; Blue­bird's gene ther­a­py takes off; Bet­ter PhI­II? At a frac­tion of ...

3 years ago
Weekly

ICER pan­el says two ALS drug can­di­dates have 'low' long-term val­ue

3 years ago
Pharma

Genen­tech hits the run­way for a New York Fash­ion Week pre­quel, fea­tur­ing SMA mod­els and adap­tive cloth­ing

3 years ago
Pharma
Marketing

Few­er than 40% of new ac­cel­er­at­ed ap­provals demon­strate 'high' ther­a­peu­tic val­ue, study says

3 years ago
FDA+
Law

Phar­ma man­u­fac­tur­ers in In­dia, US lat­est to re­ceive qual­i­ty con­trol hits from the FDA

3 years ago
Pharma
FDA+

miR Sci­en­tif­ic lights up land­marks in blue for prostate can­cer aware­ness

3 years ago
Pharma
Marketing

En­do los­es Va­sostrict patent bat­tle as sales take a hit from gener­ics

3 years ago
Pharma
Law

The mon­key­pox treat­ment and what's com­ing: A con­ver­sa­tion with the CEO mak­ing Tpoxx

3 years ago
Pharma

No­vo Nordisk pub­lish­es in­au­gur­al di­ver­si­ty and in­clu­sion re­port with poli­cies, progress and pur­suits

3 years ago
Pharma
Marketing

Nor­we­gian biotech to en­act lay­offs; Uni­ty halves its pub­lic of­fer­ing

3 years ago
News Briefing

Covid-19 roundup: EMA starts re­view of SK’s vac­cine; Aus­tralian biotech switch­ing gears away from Covid re­search

3 years ago
Coronavirus

In search for bet­ter CKD drugs, re­searchers pro­pose a new-ish tar­get for the dis­ease

3 years ago
R&D

Kymera opens up $150M PIPE fi­nanc­ing, thanks to un­ex­pect­ed of­fer from in­vestors

3 years ago
Financing

Fol­low­ing an al­most year­long wait, FDA ap­proves Ax­some's rapid-act­ing de­pres­sion drug

3 years ago
Pharma
FDA+

ICY­MI: James Sabry just signed off on a land­mark first for Roche's deal­mak­ing crew

3 years ago
Bioregnum
China

Lit­tle Nor­we­gian biotech will sell it­self for parts, as it plans to ex­plore 's­trate­gic op­tion­s'

3 years ago
R&D

Strug­gling pen­ny stock biotech lays off 40% of staffers to stay afloat — for a few more weeks

3 years ago
People

Just like start­ing over: Mod­er­na tees up an­oth­er CFO; Ge­of­frey Porges puts down his SVB pen to join Schrödinger

3 years ago
Peer Review

Bay­er gets FDA nod to ex­tend use of pop­u­lar con­tra­cep­tive IUD Mire­na

3 years ago
Pharma
FDA+

Lund­beck tries to rush its FDA-ap­proved mi­graine drug to Chi­na but fails PhI­II tri­al

3 years ago
R&D
Pharma
First page Previous page 470471472473474475476 Next page Last page
A service from the Financial Times